Related Experiment Video
Updated: Apr 24, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Ganitumab for the treatment of small-cell lung cancer
Pablo Martínez1, Paula Alexandra Sales Fidalgo, Enriqueta Felip
1Vall d´Hebron University Hospital and Vall d´Hebron Institute of Oncology, Medical Oncology Department , Barcelona , Spain efelip@vhio.net.
Introduction:
Small-cell lung cancer (SCLC) accounts for 15 - 20% of all lung cancer cases with few advances made in the systemic treatment and outcomes for extensive-stage SCLC. Many strategies have been evaluated over the past 15 years but none of these approaches has resulted in improved survival rates for patients with SCLC. The IGF receptor (IGF-R) pathway represents a potential actionable target in SCLC patients. Indeed, the IGF-R pathway is involved in cancer development and progression and regulates different vital processes including fetal development, growth and metabolism.
Areas Covered:
This review provides an overview of insulin inhibitors and the strategies undertaken in recent years with SCLC. Specifically, the article discusses ganitumab and its applicability to SCLC patients.
Expert Opinion:
At present, there is a lack of therapeutic choices for patients with advanced SCLC. Unfortunately, ganitumab, administered in combination with chemotherapy, demonstrated no clinical activity in patients with SCLC, although it could have utility with other cancers. Furthermore, insulin inhibitors may have some utility in the treatment of SCLC and further studies are required to identify subsets of patients most likely to benefit from their use. The authors also believe that it is important to determine the exact role of the IGF pathway in the pathogenesis and propagation of SCLC.
Insights
Advanced small-cell lung cancer (SCLC) lacks effective treatments. Ganitumab showed no benefit, but insulin inhibitors may help SCLC patients, requiring further research into the IGF pathway.
Area of Science:
- Oncology
- Medical Research
Background:
- Small-cell lung cancer (SCLC) represents 15-20% of lung cancer cases.
- Extensive-stage SCLC has seen limited progress in systemic treatment and patient outcomes.
- The Insulin-like Growth Factor (IGF) receptor pathway is implicated in cancer progression and vital biological processes.
Purpose of the Study:
- To review insulin inhibitors and recent therapeutic strategies for SCLC.
- To evaluate the applicability of ganitumab in SCLC patients.
Main Methods:
- Literature review of recent strategies for SCLC treatment.
- Discussion of ganitumab's efficacy in SCLC.
Main Results:
- Ganitumab, combined with chemotherapy, did not demonstrate clinical activity in SCLC patients.
- Insulin inhibitors show potential utility in SCLC treatment.
Conclusions:
- There is a significant unmet need for therapeutic options in advanced SCLC.
- Further research is needed to identify patient subsets benefiting from insulin inhibitors.
- Clarifying the role of the IGF pathway in SCLC pathogenesis is crucial.
